Graft-Versus-Host Disease (Chronic)

Comprehensive Clinical Guide: Chronic Graft-Versus-Host Disease (cGVHD)

Chronic Graft-Versus-Host Disease (cGVHD) represents the most significant long-term complication following allogeneic hematopoietic stem cell transplantation (HSCT). Unlike its acute counterpart, which is primarily driven by cytokine storms and rapid epithelial damage, cGVHD is a complex, multi-system immunologic disorder characterized by dysregulated T-cell and B-cell activity, leading to chronic inflammation, fibrosis, and immune deficiency.

1. Clinical Definition and Overview

Chronic GVHD is a systemic autoimmune-like syndrome occurring after allogeneic HSCT. While acute GVHD (aGVHD) typically occurs within the first 100 days, cGVHD generally manifests after day 100, though it can present earlier (overlap syndrome). It affects approximately 30–70% of long-term survivors, making it the leading cause of non-relapse morbidity and mortality in transplant recipients.

Key Clinical Characteristics

• Multi-organ involvement: Skin, mouth, eyes, lungs, liver, and gastrointestinal tract are primary targets.
• Pathologic hallmarks: Inflammation, fibrosis, and atrophy.
• Immune dysregulation: Loss of B-cell tolerance and impaired thymic function.

2. Pathophysiology: The Molecular Mechanism

The pathogenesis of cGVHD is a tripartite process involving donor-derived immune cells attacking host tissues.

Phase 1: Initiation and Antigen Presentation

Following HSCT, donor T-cells recognize host minor histocompatibility antigens (mHAs) presented on host antigen-presenting cells (APCs). In cGVHD, the immune response is broader than in aGVHD, involving both CD4+ and CD8+ T-cells.

Phase 2: Dysregulated Adaptive Immunity

• T-cell Polarization: A shift toward Th17 and T-follicular helper (Tfh) cell subsets, which drive B-cell activation.
• B-cell Dysfunction: Loss of regulatory B-cells (Bregs) and the emergence of pathogenic, auto-antibody-producing B-cells.
• Macrophage Activation: Donor-derived macrophages secrete profibrotic cytokines (TGF-β, PDGF), leading to collagen deposition.

Phase 3: The Fibrotic Cascade

Chronic inflammation leads to the activation of fibroblasts. TGF-β signaling induces the transformation of fibroblasts into myofibroblasts, resulting in the characteristic sclerodermatous skin changes and organ-level fibrosis (e.g., bronchiolitis obliterans).

3. Clinical Staging and Grading

The NIH Consensus Criteria are the gold standard for diagnosing and staging cGVHD.

NIH Global Severity Scoring

Organ-Specific Scoring (Summary Table)

• Skin: Erythema, maculopapular rash, lichenoid changes, or scleroderma.
• Eyes: Keratoconjunctivitis sicca (Schirmer’s test < 5mm).
• Mouth: Oral ulcers, lichenoid plaques, or salivary gland atrophy.
• Lungs: FEV1 decline or bronchiolitis obliterans syndrome (BOS).

4. Clinical Presentation: What the Clinician Sees

Clinical presentation is highly heterogeneous. Patients may present with a single organ symptom or systemic failure.

Common Presentation Patterns

1. Dermatological: Lichen planus-like lesions or sclerotic plaques that restrict joint mobility.
2. Ocular: Patients complain of "gritty" or dry eyes, photophobia, and blurred vision.
3. Oral: Severe mucosal sensitivity to acidic/spicy foods, persistent dry mouth (xerostomia), and dental decay.
4. Pulmonary: Often silent initially. Patients may present with non-productive cough, dyspnea on exertion, and decreased exercise tolerance.
5. Hepatic: Typically manifests as cholestasis (elevated alkaline phosphatase and bilirubin).

5. Differential Diagnosis

Distinguishing cGVHD from other post-transplant complications is vital for appropriate management.

• Drug Toxicity: Calcineurin inhibitor-induced nephrotoxicity or skin rashes.
• Viral Infections: CMV, EBV, or HHV-6 can mimic skin or liver GVHD.
• Relapse of Underlying Malignancy: Extramedullary relapse can mimic skin nodules or organ infiltration.
• Idiopathic Pneumonia Syndrome (IPS): Distinguishable from BOS by the rapid, acute onset of lung injury.

6. Diagnostic Testing and Evaluation

A multidisciplinary approach is required to confirm diagnosis.

• Biopsy (Gold Standard): Skin punch biopsy is the most common diagnostic tool. Histology shows subepidermal clefts, lichenoid inflammation, or dermal collagen bundles.
• Pulmonary Function Tests (PFTs): Essential for diagnosing BOS. Look for progressive decline in FEV1/FVC ratios.
• Schirmer’s Test: Quantification of tear production for ocular involvement.
• Laboratory Panel: Comprehensive Metabolic Panel (CMP) for liver enzymes; quantitative immunoglobulin levels to assess immune deficiency.

7. Risks and Management Strategies

Standard Care

• First-line therapy: Systemic corticosteroids (prednisone 0.5–1.0 mg/kg/day).
• Second-line therapy: Ruxolitinib (JAK inhibitor), Ibrutinib (BTK inhibitor), or Belumosudil (ROCK2 inhibitor).
• Supportive Care: Prophylactic antibiotics (PCP prophylaxis), topical steroids, and physical therapy for contractures.

Risks and Complications

• Infection: High risk of encapsulated bacteria and fungal infections due to chronic immunosuppression.
• Secondary Malignancies: Increased risk of squamous cell carcinoma of the skin.
• End-organ Failure: Particularly terminal lung disease or hepatic cirrhosis.

8. Long-Term Prognosis

The prognosis depends on the severity of organ involvement. While many patients achieve complete remission with prolonged therapy, a subset of patients remains steroid-dependent for years. Mortality in cGVHD is primarily driven by infection and pulmonary complications. Early intervention is the strongest predictor of positive outcomes.

9. Frequently Asked Questions (FAQ)

1. Is cGVHD the same as transplant rejection?
No. Rejection occurs when the host immune system attacks the donor graft. In cGVHD, the donor immune system (the graft) attacks the host tissues.

2. Can cGVHD be cured?
"Cure" is difficult to define. Many patients achieve long-term control and eventually taper off immunosuppressants, but some degree of immune dysregulation may persist.

3. Why do I need to see an ophthalmologist?
Ocular cGVHD can cause severe corneal scarring. Early detection of dry eyes allows for aggressive lubrication and prevention of permanent vision loss.

4. Is there a genetic predisposition to cGVHD?
Research indicates certain HLA alleles and non-HLA polymorphisms may increase risk, but it is primarily driven by the donor-recipient mismatch.

5. How long is the typical treatment duration?
Treatment is usually prolonged. Patients are often on immunosuppressive therapy for 1 to 3 years, sometimes longer.

6. Can cGVHD affect the lungs?
Yes. Bronchiolitis obliterans syndrome (BOS) is a life-threatening form of cGVHD that causes airway obstruction.

7. What is the role of physical therapy?
Physical therapy is crucial for patients with sclerodermatous cGVHD to prevent joint contractures and maintain muscle strength.

8. Are vaccines effective in cGVHD patients?
Patients on systemic immunosuppression have a poor response to vaccines. Vaccination strategies are usually deferred until the patient is off immunosuppression.

9. Why does my skin feel tight?
This is a sign of sclerotic cGVHD, where excessive collagen deposition in the dermis mimics systemic sclerosis (scleroderma).

10. What is the most effective new treatment?
Recent FDA approvals such as Belumosudil (Rezurock) have shown significant efficacy in treating fibrotic manifestations of cGVHD by targeting the ROCK2 pathway.

10. Clinical Summary Table: Therapeutic Approach

Conclusion

Chronic GVHD remains a formidable clinical challenge that requires a nuanced, patient-centered approach. By integrating early diagnostic screening, aggressive management of inflammatory symptoms, and innovative targeted therapies, clinicians can significantly improve the quality of life and survival rates for transplant recipients. The shift toward molecular-targeted agents marks a new era in the management of this complex disease, moving away from broad, toxic immunosuppression toward precision medicine.

Medical Disclaimer: This guide is for educational and informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.